193751-54-1

Basic information

• Product Name: N-1-Boc-amino-3-cyclopentene
• Synonyms: CYCLOPENT-3-ENYL-CARBAMIC ACID TERT-BUTYL ESTER;1-N-BOC-AMINO-3-CYCLOPENTENE;N-1-BOC-AMINO-3-CYCLOPENTENE;Carbamic acid, 3-cyclopenten-1-yl-, 1,1-dimethylethyl ester (9CI);tert-Butyl N-(1-cyclopent-3-enyl)carbamate;3-Cyclopenten-1-yl-carbaMic Acid 1,1-DiMethylethyl Ester;N-3-Cyclopenten-1-yl-carbaMic Acid 1,1-DiMethylethyl Ester;tert-Butyl 3-cyclopentenylcarbaMate
• CAS NO: 193751-54-1
• Molecular Formula: C₁₀H₁₇NO₂
• Molecular Weight: 183.25
• Product Categories: N-BOC;Amines;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 193751-54-1.mol

Chemical Properties

• Boiling Point: 268.877 °C at 760 mmHg
• Flash Point: 116.413 °C
• Appearance: /
• Density: 1.014 g/cm³
• Vapor Pressure: 0.00749mmHg at 25°C
• Refractive Index: 1.483
• Storage Temp.: 2-8°C
• PKA: 12.37±0.20(Predicted)
• CAS DataBase Reference: N-1-Boc-amino-3-cyclopentene(CAS DataBase Reference)
• NIST Chemistry Reference: N-1-Boc-amino-3-cyclopentene(193751-54-1)
• EPA Substance Registry System: N-1-Boc-amino-3-cyclopentene(193751-54-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 193751-54-1(Hazardous Substances Data)

Usage

Uses

Used in Surface Functionalization:
N-1-Boc-amino-3-cyclopentene is used as a functionalizing agent for silicon surfaces to introduce primary amine groups. This application is particularly relevant in the field of microelectronics and material science, where the attachment of DNA or other biomolecules to silicon surfaces is required for the development of biosensors, microfluidic devices, and other bioelectronic systems.
Used in DNA Attachment:
In the field of molecular biology and bioengineering, N-1-Boc-amino-3-cyclopentene serves as a crucial component in the attachment of DNA to silicon surfaces. This process is essential for the creation of DNA microarrays, which are widely used in genetic research, diagnostics, and personalized medicine.
Used in Chemical Synthesis:
N-1-Boc-amino-3-cyclopentene is also used as a synthetic building block in the synthesis of various organic compounds, particularly those containing cyclopentene rings. Its protecting group ensures selective reactivity, making it a valuable tool in the development of pharmaceuticals, agrochemicals, and other specialty chemicals.

InChI:InChI=1/C10H17NO2/c1-10(2,3)13-9(12)11-8-6-4-5-7-8/h4-5,8H,6-7H2,1-3H3,(H,11,12)

Upstream product

• 219844-47-0 N-(t-butyloxycarbonyl)-N-(methanesulfonyloxy)cyclopent-3-enylcarboxamide 
• 75-65-0 tert-butyl alcohol 
• 2487-95-8 4-Isocyanato-cyclopentene 
• 91469-55-5 cyclopent-3-en-1-amine hydrogen chloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 253680-54-5 methanesulfonic acid cyclopent-3-enyl ester 
• 7686-77-3 3-cyclopentene-1-carboxylic acid 
• 14320-38-8 cyclopent-3-enol 
• 216959-34-1 ethyl 2-{[(tert-butoxy)carbonyl]amino}-2-oxoacetate 
• 1018908-86-5 (tert-butoxycarbonyl-cyclopent-3-enyl-amino)-oxo-acetic acid ethyl ester 
• 71432-55-8 2-tert-butyl-1,3-diisopropylisourea 

Downstream Products

• 250659-32-6 racemic tert-butyl ((1R,3S,5S)-6-oxabicyclo[3.1.0]hexan-3-yl)carbamate 
• 216578-35-7 tert-butyl (1R,3R,5S)-6-oxabicyclo[3.1.0]hexan-3-ylcarbamate 
• 154802-92-3 (+/-)-1-hydroxy-4-[(tert-butoxycarbonyl)amino]-2-cyclopentene 
• 1154870-59-3 (±)-trans-(3-hydroxycyclopentyl)carbamic acid tert-butyl ester 
• 1154870-59-3 trans-(3-hydroxycyclopentyl)carbamic acid tert-butyl ester 
• 1154870-59-3 (cis-3-hydroxy-cyclopentyl)-carbamic acid tert-butyl ester 
• 1154870-59-3 (trans-3-hydroxy-cyclopentyl)-carbamic acid tert-butyl ester 
• 1552273-85-4 1-(cyclopent-3-en-1-yl)-5-(3-fluoro-4-(trifluoromethyl)phenyl)-1H-imidazole 
• 1552273-68-3 1-(cyclopent-3-en-1-yl)-5-phenyl-1H-imidazole 
• 1225384-36-0 benzyl (1S,3R,4S)-3,4-dihydroxycyclopentyl(methyl)carbamate 
• 1154870-59-3 (+/-)-cis-(3-hydroxy-cyclopentyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE

Peptidomimetic compounds as can inhibit neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as but not limited to stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease.

Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors

Fragment hopping, a new fragment-based approach for de novo inhibitor design focusing on ligand diversity and isozyme selectivity, is described. The core of this approach is the derivation of the minimal pharmacophoric element for each pharmacophore. Sites for both ligand binding and isozyme selectivity are considered in deriving the minimal pharmacophoric elements. Five general-purpose libraries are established: the basic fragment library, the bioisostere library, the rules for metabolic stability, the toxicophore library, and the side chain library. These libraries are employed to generate focused fragment libraries to match the minimal pharmacophoric elements for each pharmacophore and then to link the fragment to the desired molecule. This method was successfully applied to neuronal nitric oxide synthase (nNOS), which is implicated in stroke and neurodegenerative diseases. Starting with the nitroarginine-containing dipeptide inhibitors we developed previously, a small organic molecule with a totally different chemical structure was designed, which showed nanomolar nNOS inhibitory potency and more than 1000-fold nNOS selectivity. The crystallographic analysis confirms that the small organic molecule with a constrained conformation can exactly mimic the mode of action of the dipeptide nNOS inhibitors. Therefore, a new peptidomimetic strategy, referred to as fragment hopping, which creates small organic molecules that mimic the biological function of peptides by a pharmacophore-driven strategy for fragment-based de novo design, has been established as a new type of fragment-based inhibitor design. As an open system, the newly established approach efficiently incorporates the concept of early "ADME/Tox" considerations and provides a basic platform for medicinal chemistry-driven efforts.

HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE

Compounds inhibiting neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, such compounds of a formula.

Pyrimidine derivatives as IL-8 receptor antagonists

Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula I In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, —O—alkyl or —S-alkyl. A representative example is:

New route to 4-aminocyclopent-2-en-1-ols: Synthesis and enantioselective rearrangement of 4-amino-substituted cyclopentene oxides

A new route for the asymmetric synthesis of 4-aminocyclopent-2-en-1-ols (90% ee) for carbocyclic nucleoside analogue synthesis is described. The approach involves the stereoselective preparation of cis 4-amino-substituted cyclopentene oxides and subsequent chiral base-mediated rearrangement to the corresponding allylic alcohols. Full details on the synthesis and stereoselectivity of epoxidation of 4-amino-substituted cyclopentenes are presented. (C) 2000 Elsevier Science Ltd.

2-amino-5,6-dichlorobenzimidazole derivatives having antiviral activity

The present invention relates to benzimidazole derivatives of formula (I) wherein: R1 represents H, C1-4 alkyl, C3-5 cycloalkyl; R2 represents H, C1-4 alkyl; or R1 and R2 together form with the nitrogen a 4 or 5 membered heterocyclic ring; R3 represents BR4 or R4 wherein B represents a bridging group --C(O)NH--, --C(O)NC1-4 alkyl-, or C(O)O-- and R4 represents H, C1-4 alkyl, C2-6 alkenyl or halo (preferably fluoro); and each n is an integer independently selected from 0, 1, or 2 (preferably 0 or 1); and geometric isomers or mixtures thereof; and physiologically functional derivatives thereof, and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to their preparation and pharmaceutical formulations containing them.

On the possibility of carbamate-directed hydroboration. An approach to the asymmetric synthesis of 1-aminocyclopentane-1,3-dicarboxylic acid

Hydroboration (using BH3) of 1-substituted 3-cyclopentenes 3, 9 and 17 and an enantioselective synthesis of the excitatory amino acid 1- aminocyclopentane-1,3-dicarboxylic acid via asymmetric hydroboration [90% de, 45% ee using (+)-IpcBH2] of cyclopentene 17 are described.

Carbamate-directed hydroboration: Enantioselective synthesis of the excitatory amino acid 1-aminocyclopentane-1,3-dicarboxylic acid

Carbamate-directed hydroboration (using BH3) of 1-substituted 3- cyclopentenes 2, 6 and 9 and an enantioselective synthesis of the excitatory amine acid 1-aminocyclopentane-1,3-dicarboxylic acid via carbamate-directed asymmetric hydroboration [90% de, 45% ee using (+)-IpcBH2] of cyclopentene 2 are described.

Synthesis and enantioselective rearrangement of 4-amino-substituted cyclopentene oxides

Several N-mono- and diprotected alkenes have been prepared and the stereoselectivity of their epoxidation has been investigated: N-monoprotected alkenes give cis epoxides preferentially (due to hydrogen bonding directed epoxidations) whereas N-diprotected alkenes produce trans epoxides exclusively (due to steric effects). Chiral lithium amide base-mediated rearrangement of a cis-monoprotected epoxide generated the corresponding amino-cyclopentenol in good yield and with an enantiomeric excess of 60%.